Technology | Nuclear Imaging | January 16, 2019

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry

MIM SurePlan MRT provides quantitative SPECT reconstruction and voxel-based absorbed dose calculation for molecular radiotherapy

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry

January 16, 2019 — MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy (MRT) dosimetry.

MRT is an effective form of therapy that uses radiopharmaceuticals such as Lutathera (Lu-177 DOTATATE) and Azedra (I-131 iobenguane) to target tumors based on certain receptors that these tumors express.

Until now, there has not been an effective way to measure the absorbed dose from MRT for an individual patient. This is due to a lack of access to quantitative single photon emission computed tomography (SPECT) images and tools for calculating dose on the patient's own anatomy. MIM SurePlan MRT provides both quantitative SPECT reconstruction and voxel-based absorbed dose calculation by utilizing the patient's own images, allowing for personalized dosimetry measurements.

MIM SurePlan MRT provides timesaving tools for organ and tumor segmentation, deformable registration and voxel-based dosimetry for molecular radiotherapy. Other features of MIM SurePlan MRT include multi-tracer theranostics support, quantitative SPECT and planar corrections, and dosimetry reporting tools.

MIM Software will demonstrate MIM SurePlan MRT at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Mid-Winter Meeting, Jan. 18-19 in Palm Springs, Calif.

For more information: www.mimsoftware.com

Related Content

MD Anderson and Varian Partner to Optimize Radiation Oncology Treatment
News | Treatment Planning | October 18, 2019
The University of Texas MD Anderson Cancer Center and Varian announced a new strategic collaboration to develop an...
GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent
News | Prostate Cancer | October 16, 2019
GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane...
Videos | Radiation Oncology | October 11, 2019
Lorraine Drapek, DNP, nurse practitioner, radiation oncology, GI service,...
Patient Treatments With ViewRay's MRIdian Linac Begin in New England
News | Image Guided Radiation Therapy (IGRT) | October 08, 2019
ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac...
Videos | Prostate Cancer | September 30, 2019
Bill Hartsell, M.D., medical director of the Northwestern Medicine Proton Center in Warrenville, Ill., discusses the
eBook on Hypofractionation in the Age of Value-based Care

eBook on Hypofractionation in the Age of Value-based Care

Sponsored Content | Case Study | Radiation Therapy | September 30, 2019
Hypofractionated and ultrahypofractionated radiation therapy — increasing dose per fraction to enable significantly f
AI Accurately Predicts Radiotherapy Side Effects for Head and Neck Cancer Patients
News | Artificial Intelligence | September 26, 2019
For the first time, a sophisticated computer model has been shown to accurately predict two of the most challenging...